FATE Q4 2023 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-96.2% YoY

Gross Profit

-$3M-191.5% margin

Operating Income

-$48M-2868.4% margin

Net Income

-$44M-2632.6% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

-13.8%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$506M

Total Liabilities

$138M

Stockholders' Equity

$368M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$44M	-96.2%
Gross Profit	-$3M	-$43M	+92.5%
Operating Income	-$48M	-$64M	+25.4%
Net Income	-$44M	-$56M	+21.7%